https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
04%; 95% CI = 0.29-13.62) was lower than the non-pCR group (14.62%; 95% CI = 10.12-20.87). Higher histological grade was also associated high pCR rate (52.0% vs 40.0%). The use of PLD-containing chemotherapeutics in neoadjuvant settings might have benefits for non-metastatic operable breast cancer in Taiwanese females. The use of PLD-containing chemotherapeutics in neoadjuvant settings might have benefits for non-metastatic operable breast cancer in Taiwanese females.Professor Sir Mark Walport, FRS, FMed Sci, FRCP, physician
Beğen
Yorum Yap
Paylaş
